Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


European Journal of Endocrinology, Vol 135, Issue 6, 666-671
Copyright © 1996 by European Society of Endocrinology
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bollerslev, J
Right arrow Articles by Christiansen, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bollerslev, J
Right arrow Articles by Christiansen, J.

Articles

Dose-dependent effects of recombinant human growth hormone on biochemical markers of bone and collagen metabolism in adult growth hormone deficiency

J Bollerslev, J Moller, S Thomas, O Djoseland, and JS Christiansen

Department of Medical Endocrinology, National University Hospital, Oslo, Norway.

Administration of growth hormone (GH) to patients with growth hormone deficiency (GHD) has beneficial effects, but so far has been employed only empirically. We have, therefore, investigated the dose-dependent effect of GH on target tissue by studying biochemical markers of bone and collagen turnover in GHD. Then patients with GHD (nine males and one female aged 21-43 years, mean age 28 years) participated in the study. Growth hormone deficiency was defined as a peak serum GH response of less than 15 mU/l in two provocation tests. After a 4-week run-in period, the study population received increasing doses of GH at 4-week intervals (1, 2 and 4 U/m2). Blood samples were collected in the fasting state at 7.00 h on the last day of each period and assayed for serum levels of osteocalcin (S-BGP), bone alkaline phosphatase (B-ALP), C-terminal propeptide of type I collagen (S-PICP), carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen (S-ICTP) and N-terminal propeptide of type III collagen (S-PIIINP). Following replacement therapy, serum insulin-like growth factor I and insulin-like growth factor binding protein 3 increased sequentially with time (p < 0.001 and p < 0.001, MANOVA) and the values were elevated significantly over baseline levels after treatment with 1 U/m2. Serum BGP values were below normal at the start of the study and increased gradually following GH treatment to levels in the low-normal range. Baseline values for serum bone alkaline phosphatase (B-ALP), PICP and PIIINP were within the normal range. The collagen parameters increased with GH replacement (p < 0.001, MANOVA) to levels above normal, whereas B-ALP stayed within normal limits. Serum ICTP values were elevated above the normal range at baseline, indicating increased bone resorption in GHD. A linear increase in values was observed with GH treatment (p < 0.001, MANOVA). Serum ICTP did not correlate significantly with the bone formative parameters but was correlated positively to PIIINP. The sensitivity of S-ICTP as a bone resorptive marker is thus questioned. In conclusion, a dose-dependent increase in markers of growth hormone metabolism and in biochemical markers of both bone and non-bone collagen synthesis was seen following incremental doses of GH in GHD.


This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
C. Parkinson, M. Kassem, L. Heickendorff, A. Flyvbjerg, and P. J. Trainer
Pegvisomant-Induced Serum Insulin-Like Growth Factor-I Normalization in Patients with Acromegaly Returns Elevated Markers of Bone Turnover to Normal
J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5650 - 5655.
[Abstract] [Full Text] [PDF]


Home page
Br. J. Sports. Med.Home page
M J Rennie
Claims for the anabolic effects of growth hormone: a case of the Emperor's new clothes?
Br. J. Sports Med., April 1, 2003; 37(2): 100 - 105.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
A. S. Khan, D. C. Sane, T. Wannenburg, and W. E. Sonntag
Growth hormone, insulin-like growth factor-1 and the aging cardiovascular system
Cardiovasc Res, April 1, 2002; 54(1): 25 - 35.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Longobardi, N. Keay, C. Ehrnborg, A. Cittadini, T. Rosén, R. Dall, M. A. Boroujerdi, E. E. Bassett, M. L. Healy, C. Pentecost, et al.
Growth Hormone (GH) Effects on Bone and Collagen Turnover in Healthy Adults and Its Potential as a Marker of GH Abuse in Sports: A Double Blind, Placebo-Controlled Study
J. Clin. Endocrinol. Metab., April 1, 2000; 85(4): 1505 - 1512.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
J. D. Wallace, R. C. Cuneo, P. A. Lundberg, T. Rosén, J. O. L. Jørgensen, S. Longobardi, N. Keay, L. Sacca, J. S. Christiansen, B.-A. Bengtsson, et al.
Responses of Markers of Bone and Collagen Turnover to Exercise, Growth Hormone (GH) Administration, and GH Withdrawal in Trained Adult Males
J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 124 - 133.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
T. Ueland, J. Bollerslev, T. B. Hansen, E. N. Ebbesen, L. Mosekilde, K. Brixen, A. Flyvbjerg, and O. Djøseland
Increased Cortical Bone Content of Insulin-Like Growth Factors in Acromegalic Patients
J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 123 - 127.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
M. A. McNurlan, P. J. Garlick, R. A. Frost, K. A. DeCristofaro, C. H. Lang, R. T. Steigbigel, J. Fuhrer, and M. Gelato
Albumin Synthesis and Bone Collagen Formation in Human Immunodeficiency Virus-Positive Subjects: Differential Effects of Growth Hormone Administration
J. Clin. Endocrinol. Metab., September 1, 1998; 83(9): 3050 - 3055.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 European Society of Endocrinology.